Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes

References

• Czarnecka AM, Synoradzki K, Firlej W, et al. Molecular biology of osteosarcoma. Cancers. 2020;12(8):2130.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125(1):229–234.
   PubMed Web of Science ®Google Scholar
• Corre I, Verrecchia F, Crenn V, et al. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 2020;9(4):976.
   Web of Science ®Google Scholar
• Gaspar N, Occean B-V, Pacquement H, et al. Results of methotrexate–etoposide–ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/Sarcome-09 study. Eur J Cancer. 2018;88:57–66.
   PubMed Web of Science ®Google Scholar
• Wang L, Xue G-B. Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis. Biochem Biophys Res Commun. 2018;495(1):27–34.
   PubMed Web of Science ®Google Scholar
• Hashemi Goradel N, Ghiyami‐Hour F, Jahangiri S, et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J Cell Physiol. 2018;233(4):2902–2910.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang F, Li M, et al. Self‐stabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma. Adv Sci. 2018;5(5):1700821.
   Web of Science ®Google Scholar
• Zhang Y, Cai L, Li D, et al. Tumor microenvironment-responsive hyaluronate–calcium carbonate hybrid nanoparticle enables effective chemotherapy for primary and advanced osteosarcomas. Nano Res. 2018;11(9):4806–4822.
   Web of Science ®Google Scholar
• Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, et al. Nanomedicine review: clinical developments in liposomal applications. Cancer Nano. 2019;10(1):1–40.
   Web of Science ®Google Scholar
• Mangal S, Gao W, Li T, et al. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017;38(6):782–797.
   PubMed Web of Science ®Google Scholar
• Hossen S, Hossain MK, Basher MK, et al. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res. 2019;15:1–18.
   PubMed Web of Science ®Google Scholar
• Ahmad SS, Reinius MAV, Hatcher HM, et al. Anticancer chemotherapy in teenagers and young adults: managing long term side effects. BMJ. 2016;354:i4567.
   PubMedGoogle Scholar
• Yan L, Shen J, Wang J, et al. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response. 2020;18(3):1559325820936161.
   Web of Science ®Google Scholar
• Ariffin AB, Forde PF, Jahangeer S, et al. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res. 2014;74(10):2655–2662.
   PubMed Web of Science ®Google Scholar
• Lane RJ, Khin NY, Pavlakis N, et al. Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. Future Oncol. 2018;14(7):647–663.
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Nie Y, et al. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166.
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):1–13.
   PubMedGoogle Scholar
• Ye Q, Liu K, Shen Q, et al. Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front Oncol. 2019;9:487.
   PubMed Web of Science ®Google Scholar
• Bae KH, Chung HJ, Park TG. Nanomaterials for cancer therapy and imaging. Mol Cells. 2011;31(4):295–302.
   PubMed Web of Science ®Google Scholar
• Lungu II, Grumezescu AM, Volceanov A, et al. Nanobiomaterials used in cancer therapy: an up-to-date overview. Molecules. 2019;24(19):3547.
   Web of Science ®Google Scholar
• Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. BIO Integr. 2021;2(2):57–60.
   Google Scholar
• Wei L, Chen J, Ding J. Sequentially stimuli-responsive anticancer nanomedicines. Nanomedicine. 2021;16(4):261–264.
   PubMed Web of Science ®Google Scholar
• Feng X, Xu W, Xu X, et al. Cystine proportion regulates fate of polypeptide nanogel as nanocarrier for chemotherapeutics. Sci China Chem. 2021;64(2):293–301.
   Web of Science ®Google Scholar
• Feng X, Xu W, Liu J, et al. Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy. Sci Bull. 2021;66(4):362–373.
   Web of Science ®Google Scholar
• Cai J, Qian K, Zuo X, et al. PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer. J Biomater Appl. 2019;33(10):1394–1406.
   PubMed Web of Science ®Google Scholar
• Alemrayat B, Elhissi A, Younes HM. Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy. Pharm Dev Technol. 2019;24(2):235–242.
   PubMed Web of Science ®Google Scholar
• Emami F, Banstola A, Vatanara A, et al. Doxorubicin and anti-PD-L1 antibody conjugated gold nanoparticles for colorectal cancer photochemotherapy. Mol Pharm. 2019;16(3):1184–1199.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang S, Zhang S, et al. Mesoporous silica nanoparticle-based combination of NQO1 inhibitor and 5-fluorouracil for potent antitumor effect against head and neck squamous cell carcinoma (HNSCC). Nanoscale Res Lett. 2019;14:1–12.
   PubMed Web of Science ®Google Scholar
• Esfandiarpour-Boroujeni S, Bagheri-Khoulenjani S, Mirzadeh H, et al. Fabrication and study of curcumin loaded nanoparticles based on folate-chitosan for breast cancer therapy application. Carbohydr Polym. 2017;168:14–21.
   PubMed Web of Science ®Google Scholar
• Zhao R, Li T, Zheng G, et al. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials. 2017;143:1–16.
   PubMed Web of Science ®Google Scholar
• Zhai J, Luwor RB, Ahmed N, et al. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl Mater Interfaces. 2018;10(30):25174–25185.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu J, Xie F, et al. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomedicine. 2019;14:9199–9216.
   PubMed Web of Science ®Google Scholar
• Khademi Z, Lavaee P, Ramezani M, et al. Co-delivery of doxorubicin and aptamer against forkhead box M1 using chitosan-gold nanoparticles coated with nucleolin aptamer for synergistic treatment of cancer cells. Carbohydr Polym. 2020;248:116735.
   PubMed Web of Science ®Google Scholar
• Maia ALC, de Ferreira CA, de Barros ALB, et al. Vincristine-loaded hydroxyapatite nanoparticles as a potential delivery system for bone cancer therapy. J Drug Target. 2018;26(7):592–603.
   PubMed Web of Science ®Google Scholar
• Liu B, Han L, Liu J, et al. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017;12:955–968.
   PubMed Web of Science ®Google Scholar
• Chaudhary Z, Subramaniam S, Khan GM, et al. Encapsulation and controlled release of resveratrol within functionalized mesoporous silica nanoparticles for prostate cancer therapy. Front Bioeng Biotechnol. 2019;7:225.
   PubMed Web of Science ®Google Scholar
• Iacobazzi RM, Porcelli L, Lopedota AA, et al. Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. Int J Pharm. 2017;528(1–2):485–497.
   PubMedGoogle Scholar
• Tao X, Tao T, Wen Y, et al. Novel delivery of mitoxantrone with hydrophobically modified pullulan nanoparticles to inhibit bladder cancer cell and the effect of nano-drug size on inhibition efficiency. Nanoscale Res Lett. 2018;13:1–12.
   PubMed Web of Science ®Google Scholar
• Pan Q, Tian J, Zhu H, et al. Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer. ACS Biomater Sci Eng. 2020;6(4):2175–2185.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Merino M, Shenol A, et al. Optimization and in-vitro/in-vivo evaluation of doxorubicin-loaded chitosan–alginate nanoparticles using a melanoma mouse model. Int J Pharm. 2019;556:1–8.
   PubMedGoogle Scholar
• Hanurry EY, Mekonnen TW, Andrgie AT, et al. Biotin-Decorated PAMAM G4.5 dendrimer nanoparticles to enhance the delivery, anti-proliferative, and apoptotic effects of chemotherapeutic drug in cancer cells. Pharmaceutics. 2020;12(5):443.
   Web of Science ®Google Scholar
• Gawde KA, Sau S, Tatiparti K, et al. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B Biointerfaces. 2018;167:8–19.
   PubMed Web of Science ®Google Scholar
• Pishavar E, Ramezani M, Hashemi M. Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2019;45(12):1931–1939.
   PubMed Web of Science ®Google Scholar
• Li Z, Tan S, Li S, et al. Cancer drug delivery in the nano era: an overview and perspectives (review). Oncol Rep. 2017;38(2):611–624.
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Giuliano E, Eeda V, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:601626.
   PubMed Web of Science ®Google Scholar
• Irmak G, Öztürk MG, Gümüşderelioğlu M. Salinomycin encapsulated PLGA nanoparticles eliminate osteosarcoma cells via inducing/inhibiting multiple signaling pathways: comparison with free salinomycin. J Drug Deliv Sci Technol. 2020;58:101834.
   Web of Science ®Google Scholar
• Wang B, Yu X-C, Xu S-F, et al. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnol. 2015;13:1–11.
   PubMed Web of Science ®Google Scholar
• Hung H-I, Klein OJ, Peterson SW, et al. PLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitro. Sci Rep. 2016;6:1–13.
   PubMed Web of Science ®Google Scholar
• Chen B, Yang J-Z, Wang L-F, et al. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in osteosarcoma. BMC Cancer. 2015;15(1):1–9.
   PubMedGoogle Scholar
• Li S, Xiong Y, Zhang X. Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma. Biomed Pharmacother. 2017;90:872–879.
   PubMed Web of Science ®Google Scholar
• Liu P, Sun L, Zhou D, et al. Development of alendronate-conjugated poly (lactic-co-glycolic acid)-dextran nanoparticles for active targeting of cisplatin in osteosarcoma. Sci Rep. 2015;5:1–12.
   Web of Science ®Google Scholar
• Sharma A, Goyal AK, Rath G. Recent advances in metal nanoparticles in cancer therapy. J Drug Target. 2018;26(8):617–632.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Jeyaraj M, Kang M-H, et al. Tangeretin-assisted platinum nanoparticles enhance the apoptotic properties of doxorubicin: combination therapy for osteosarcoma treatment. Nanomaterials. 2019;9(8):1089.
   Web of Science ®Google Scholar
• Seshadri VD. Zinc oxide nanoparticles from cassia auriculata flowers showed the potent antimicrobial and in vitro anticancer activity against the osteosarcoma MG-63 cells. Saudi J Biol Sci. 2021;28(7):4046–4054.
   PubMed Web of Science ®Google Scholar
• He G, Ma Y, Zhu Y, et al. Cross talk between autophagy and apoptosis contributes to ZnO nanoparticle‐induced human osteosarcoma cell death. Adv Healthc Mater. 2018;7(17):1800332.
   Web of Science ®Google Scholar
• Du S, Li J, Du C, et al. Overendocytosis of superparamagnetic iron oxide particles increases apoptosis and triggers autophagic cell death in human osteosarcoma cell under a spinning magnetic field. Oncotarget. 2017;8(6):9410–9424.
   PubMedGoogle Scholar
• Lim D-J, Sim M, Oh L, et al. Carbon-based drug delivery carriers for cancer therapy. Arch Pharm Res. 2014;37(1):43–52.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Petibone D, Xu Y, et al. Toxicity and efficacy of carbon nanotubes and graphene: the utility of carbon-based nanoparticles in nanomedicine. Drug Metab Rev. 2014;46(2):232–246.
   PubMed Web of Science ®Google Scholar
• Maiti D, Tong X, Mou X, et al. Carbon-based nanomaterials for biomedical applications: a recent study. Front Pharmacol. 2018;9:1401.
   PubMed Web of Science ®Google Scholar
• Jaleel JA, Pramod K. Artful and multifaceted applications of carbon dot in biomedicine. J Control Release. 2018;269:302–321.
   PubMed Web of Science ®Google Scholar
• Chauhan S, Jain N, Nagaich U. Nanodiamonds with powerful ability for drug delivery and biomedical applications: recent updates on in vivo study and patents. J Pharm Anal. 2020;10(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tiwari H, Karki N, Pal M, et al. Functionalized graphene oxide as a nanocarrier for dual drug delivery applications: the synergistic effect of quercetin and gefitinib against ovarian cancer cells. Colloids Surf B Biointerfaces. 2019;178:452–459.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen J, Wu W, et al. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma. Acta Biomater. 2020;109:229–243.
   PubMed Web of Science ®Google Scholar
• Lu S-L, Wang Y-H, Liu G-F, et al. Graphene oxide nanoparticle-loaded ginsenoside Rg3 improves photodynamic therapy in inhibiting malignant progression and stemness of osteosarcoma. Front Mol Biosci. 2021;8:663089.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Blais M-O, Harris GM, et al. PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells. PLoS One. 2013;8(12):e81947.
   PubMed Web of Science ®Google Scholar
• Yan X, Yang W, Shao Z, et al. Triggering of apoptosis in osteosarcoma cells by graphene/single-walled carbon nanotube hybrids via the ROS-mediated mitochondrial pathway. J Biomed Mater Res A. 2017;105(2):443–453.
   PubMed Web of Science ®Google Scholar
• Singh D, Singh S, Sahu J, et al. Ceramic nanoparticles: recompense, cellular uptake and toxicity concerns. Artif Cells Nanomed Biotechnol. 2016;44(1):401–409.
   PubMed Web of Science ®Google Scholar
• Thomas SC, Kumar Mishra P, Talegaonkar S. Ceramic nanoparticles: fabrication methods and applications in drug delivery. Curr Pharm Des. 2015;21:6165–6188.
   PubMed Web of Science ®Google Scholar
• Moreno-Vega A-I, Gomez-Quintero T, Nunez-Anita R-E, et al. Polymeric and ceramic nanoparticles in biomedical applications. J Nanotechnol. 2012;2012:1–10.
   Google Scholar
• Qing F, Wang Z, Hong Y, et al. Selective effects of hydroxyapatite nanoparticles on osteosarcoma cells and osteoblasts. J Mater Sci Mater Med. 2012;23(9):2245–2251.
   PubMed Web of Science ®Google Scholar
• Wang R, Liu W, Wang Q, et al. Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway. Biomater Sci. 2020;8(16):4426–4437.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yi Q, Tang L. The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review. J Exp Clin Cancer Res. 2019;38:1–11.
   PubMed Web of Science ®Google Scholar
• Qu Y, Kang M, Cheng X, et al. Chitosan-coated titanium dioxide-embedded paclitaxel nanoparticles enhance anti-tumor efficacy against osteosarcoma. Front Oncol. 2020;10:1837.
   Web of Science ®Google Scholar
• Ai J, Liu B, Liu W. Folic acid-tagged titanium dioxide nanoparticles for enhanced anticancer effect in osteosarcoma cells. Mater Sci Eng C Mater Biol Appl. 2017;76:1181–1187.
   PubMed Web of Science ®Google Scholar
• Singh J, Jain K, Mehra NK, et al. Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers. Artif Cells Nanomed Biotechnol. 2016;44(7):1626–1634.
   PubMed Web of Science ®Google Scholar
• Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Shao N, et al. Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. Acta Biomater. 2015;17:115–124.
   PubMed Web of Science ®Google Scholar
• Yan Y, Gao X, Zhang S, et al. A carboxyl-terminated dendrimer enables osteolytic lesion targeting and photothermal ablation of malignant bone tumors. ACS Appl Mater Interfaces. 2019;11(1):160–168.
   PubMed Web of Science ®Google Scholar
• Wang Z, Deng X, Ding J, et al. Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: a review. Int J Pharm. 2018;535(1–2):253–260.
   PubMed Web of Science ®Google Scholar
• Cagel M, Tesan FC, Bernabeu E, et al. Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm. 2017;113:211–228.
   PubMed Web of Science ®Google Scholar
• Xi Y, Jiang T, Yu Y, et al. Dual targeting curcumin loaded alendronate–hyaluronan–octadecanoic acid micelles for improving osteosarcoma therapy. Int J Nanomedicine. 2019;14:6425–6437.
   PubMed Web of Science ®Google Scholar
• Fang Z, Sun Y, Xiao H, et al. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle. Biomed Pharmacother. 2017;85:160–168.
   PubMed Web of Science ®Google Scholar
• Li Y, Hou H, Zhang P, et al. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv. 2020;27(1):1044–1053.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Saraf S, Jain A, Tiwari A, et al. Advances in liposomal drug delivery to cancer: an overview. J Drug Deliv Sci Technol. 2020;56:101549.
   Web of Science ®Google Scholar
• Li M, Du C, Guo N, et al. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–653.
   PubMed Web of Science ®Google Scholar
• Kanásová M, Nesměrák K. Systematic review of liposomes’ characterization methods. Monatsh Chem. 2017;148(9):1581–1593.
   Web of Science ®Google Scholar
• Smith MC, Crist RM, Clogston JD, et al. Zeta potential: a case study of cationic, anionic, and neutral liposomes. Anal Bioanal Chem. 2017;409(24):5779–5787.
   PubMed Web of Science ®Google Scholar
• Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2(2):81–87.
   PubMedGoogle Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–10966.
   PubMed Web of Science ®Google Scholar
• Ong SGM, Ming LC, Lee KS, et al. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016;8(3):25.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu H, Yu T, et al. Determination of entrapment efficiency of superoxide dismutase mimic liposomes by mini-column centrifugation-UV spectrophotometry. Chin J New Drugs. 2011;10:1–10.
   Google Scholar
• Wallenwein CM, Nova MV, Janas C, et al. A dialysis-based in vitro drug release assay to study dynamics of the drug–protein transfer of temoporfin liposomes. Eur J Pharm Biopharm. 2019;143:44–50.
   PubMed Web of Science ®Google Scholar
• Berger N, Sachse A, Bender J, et al. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223(1–2):55–68.
   PubMed Web of Science ®Google Scholar
• Wang X-H, Cai L-L, Zhang X-Y, et al. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharm. 2011;410(1–2):169–174.
   PubMed Web of Science ®Google Scholar
• Ajeeshkumar KK, Aneesh PA, Raju N, et al. Advancements in liposome technology: preparation techniques and applications in food, functional foods, and bioactive delivery: a review. Compr Rev Food Sci Food Saf. 2021;20(2):1280–1306.
   PubMed Web of Science ®Google Scholar
• Subramani T, Ganapathyswamy H. An overview of liposomal nano-encapsulation techniques and its applications in food and nutraceutical. J Food Sci Technol. 2020;57(3):1–11.
   PubMedGoogle Scholar
• Choudhury A, Sonowal K, Laskar RE, et al. Liposome: a carrier for effective drug delivery. J Appl Pharm Res. 2020;8(1):22–28.
   Google Scholar
• Ahmed KS, Hussein SA, Ali AH, et al. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742–761.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:1–9.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(4):12.
   PubMed Web of Science ®Google Scholar
• Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995;13(4):996–1003.
   PubMed Web of Science ®Google Scholar
• Fumagalli L, Zucchetti M, Parisi I, et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharmacol. 2000;45(6):495–501.
   PubMed Web of Science ®Google Scholar
• Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11(11):2186–2193.
   PubMed Web of Science ®Google Scholar
• Caliskan Y, Dalgic AD, Gerekci S, et al. A new therapeutic combination for osteosarcoma: gemcitabine and clofazimine co-loaded liposomal formulation. Int J Pharm. 2019;557:97–104.
   PubMed Web of Science ®Google Scholar
• Wu G, Fang Y-Z, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489–492.
   PubMed Web of Science ®Google Scholar
• Aon MA, Cortassa S, O'Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta. 2010;1797(6–7):865–877.
   PubMed Web of Science ®Google Scholar
• Meng F, Hennink WE, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials. 2009;30(12):2180–2198.
   PubMed Web of Science ®Google Scholar
• Guo X, Cheng Y, Zhao X, et al. Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnol. 2018;16:1–10.
   PubMed Web of Science ®Google Scholar
• Yin F, Wang Z, Jiang Y, et al. Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. Nanomedicine. 2020;23:102085.
   PubMed Web of Science ®Google Scholar
• Yin X, Chi Y, Guo C, et al. Chitooligosaccharides modified reduction-sensitive liposomes: enhanced cytoplasmic drug delivery and osteosarcomas-tumor inhibition in animal models. Pharm Res. 2017;34(10):2172–2184.
   PubMed Web of Science ®Google Scholar
• Yin X, Feng S, Chi Y, et al. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chitooligosaccharides for the therapy of osteosarcoma. Drug Deliv. 2018;25(1):900–908.
   PubMed Web of Science ®Google Scholar
• Chi Y, Yin X, Sun K, et al. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release. 2017;261:113–125.
   PubMed Web of Science ®Google Scholar
• Feng S, Wu Z-X, Zhao Z, et al. Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of orthotopic osteosarcoma. ACS Appl Mater Interfaces. 2019;11(7):7357–7368.
   PubMed Web of Science ®Google Scholar
• Zheng P, Liu Y, Chen J, et al. Targeted pH-responsive polyion complex micelle for controlled intracellular drug delivery. Chin Chem Lett. 2020;31(5):1178–1182.
   Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Vyas SP. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2015;22(3):231–242.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Sheikhha MH, et al. New liposomal doxorubicin nanoformulation for osteosarcoma: drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017;90(3):368–379.
   PubMed Web of Science ®Google Scholar
• Gong T, Su X-T, Xia Q, et al. Biodegradable combinatorial drug loaded pH-sensitive liposomes for enhanced osteosarcoma therapeutics. J Biomater Tissue Eng. 2017;7(10):952–961.
   Web of Science ®Google Scholar
• Naderinezhad S, Amoabediny G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Adv. 2017;7(48):30008–30019.
   Web of Science ®Google Scholar
• Shi Y, Moon M, Dawood S, et al. Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011;36(4):296–305.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang C, Wang W, et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Sci Rep. 2016;6:1–12.
   PubMed Web of Science ®Google Scholar
• López-Alarcón C, Denicola A. Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays. Anal Chim Acta. 2013;763:1–10.
   PubMed Web of Science ®Google Scholar
• dos Santos Ferreira D, de Oliveira Pinto BLJ, Kumar V, et al. Evaluation of antitumor activity and cardiac toxicity of a bone-targeted pH-sensitive liposomal formulation in a bone metastasis tumor model in mice. Nanomedicine. 2017;13(5):1693–1701.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev. 1995;16(2–3):285–294.
   Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013;8(9):1509–1528.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Naderinezhad S, et al. EphA2 targeted doxorubicin-nanoliposomes for osteosarcoma treatment. Pharm Res. 2017;34(12):2891–2900.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Naderinezhad S, et al. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance. Int J Nanomedicine. 2018;13:3853–3866.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Katsumi H, Hibino N, et al. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis. Biomaterials. 2018;154:74–85.
   PubMed Web of Science ®Google Scholar
• Wu H, Luo Y, Xu D, et al. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. Int J Biol Macromol. 2020;164:2583–2597.
   PubMed Web of Science ®Google Scholar